D’Angelo, Sandra P. http://orcid.org/0000-0002-3736-3783
Richards, Allison L.
Conley, Anthony P.
Woo, Hyung Jun
Dickson, Mark A.
Gounder, Mrinal
Kelly, Ciara http://orcid.org/0000-0002-4393-8088
Keohan, Mary Louise
Movva, Sujana
Thornton, Katherine
Rosenbaum, Evan
Chi, Ping
Nacev, Benjamin http://orcid.org/0000-0003-4991-2492
Chan, Jason E. http://orcid.org/0000-0003-0552-8544
Slotkin, Emily K.
Kiesler, Hannah
Adamson, Travis http://orcid.org/0000-0001-5055-0842
Ling, Lilan
Rao, Pavitra
Patel, Shreyaskumar
Livingston, Jonathan A. http://orcid.org/0000-0002-1337-3282
Singer, Samuel
Agaram, Narasimhan P.
Antonescu, Cristina R. http://orcid.org/0000-0002-9717-8205
Koff, Andrew
Erinjeri, Joseph P.
Hwang, Sinchun
Qin, Li-Xuan
Donoghue, Mark T. A.
Tap, William D.
Funding for this research was provided by:
Bristol-Myers Squibb
Nektar Therapeutics
Article History
Received: 18 October 2021
Accepted: 23 May 2022
First Online: 16 June 2022
Competing interests
: S.P.D. reports consulting or advisory roles at EMD Serono, Amgen, Nektar, Immune Design, GlaxoSmithKline, Incyte, Merck, Adaptimmune, and Immunocore. She reports research funding from EMD Serono, Amgen, Merck, Incyte, Nektar, Bristol-Meyers Squibb, and Deciphera, as well as travel expenses from Adaptimmune, EMD Serono, and Nektar. She also reports participation on a Data Safety Monitoring Board or Advisory Board for GlaxoSmithKline, Nektar, Adaptimmune, and Merck. A.P.C. reports research funding from Chordoma Foundation/Cancer Research Institute, Chordoma Foundation, Lilly Pharmaceuticals, Roche Pharmaceuticals/Ignyta, NantPharma, and Bavarian Nordic, as well as consulting fees from Deciphera, Inhbrx, Bayer Pharmaceuticals, and NovellusDX. He has received honoraria from Medscape and Onclive. M.G. reports consulting fees from pharmaceutical companies: Ayala, Bayer, Boehringer Ingelheim, Daiichi, Epizyme, Karyopharm, Springworks, Tracon and TYME; consultation fees from: Flatiron Health, Guidepoint, GLG, Medscape, More Health, Physicians Education Resource and touchIME; royalty fees from UpToDate; patents with MSKCC (GODDESS PRO); uncompensated research with Foundation Medicine, Rain and Athenex. Grants from Food and Drug Administration (R01 FD005105) and the National Cancer Institute, National Institutes of Health (P30CA008748)—core grant (CCSG shared resources and core facility). C.K. reports consulting fees from Exicure and that her spouse is employed at Daiichi Sankyo. S.M. reports research funding from Ascentage Pharmaand Hutchinson MediPharma Limited. K.T. is on the advisory board at GSK. B.N. reports uncompensated provision of services to Delphi Diagnostics, QuadW Foundation, and Rapafusyn Pharmaceuticals. J.E.C. reports research support from Cytek. T.A. reports stock options for BAYRY, CPRX, GSK, TAK, PFE and JNJ. S.P. reports research funding from Blueprint Medicines and Hutchison MediPharma, as well as consultant fees/honoraria from Deciphera, Daichi Sankyo, Dova Pharmaceuticals, and Epizyme. J.A.L. reports research funding from REPARE Therapeutics, Roche/Genentech, Exelixis, Osteosarcoma Institute and CPRIT, as well as consulting fees from ITM and honoraria from Onclive. He is a NCCN Adolescent and Young Adult Oncology Guidelines Committee Member. W.D.T. reports personal fees from Eli Lilly, personal fees from EMD Serono, personal fees from Mundipharma, personal fees from C4 Therapeutics, personal fees from Daiichi Sankyo, personal fees from Blueprint, personal fees from GlaxoSmithKline, personal fees from Agios Pharmaceuticals, personal fees from NanoCarrier, personal fees from Deciphera, personal fees from Adcendo, personal fees from Ayala Pharmaceuticals, personal fees from Kowa, personal fees from Servier, personal fees from AbMaxBio, outside the submitted work; In addition, Dr. Tap has a patent Companion Diagnostic for CDK4 inhibitors - 14/854,329 pending to MSKCC/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03 pending to MSKCC/SKI and Scientific Advisory Board - Certis Oncology Solutions, Stock Ownership. He is Co-Founder at Atropos Therapeutics with Stock Ownership and on the Scientific Advisory Board at Innova Therapeutics. All other authors declare no potential conflicts.